Newly discovered anti-inflammatory properties of the benzamides and nicotinamides

被引:0
作者
Ronald W. Pero
Bengt Axelsson
Dietmar Siemann
David Chaplin
Graeme Dougherty
机构
[1] University of Lund,Section for Molecular Ecogenetics, Department of Cell and Molecular Biology
[2] Wallenberg Laboratory,Radiation Oncology
[3] Astra-Draco AB,undefined
[4] University of Florida; Shanda Cancer Center,undefined
[5] Tumour Microcirculation Group,undefined
[6] Gray Laboratory,undefined
[7] Mount Vemon Hospital,undefined
[8] Terry Fox Laboratories,undefined
[9] British Columbia Cancer Research Center,undefined
来源
Molecular and Cellular Biochemistry | 1999年 / 193卷
关键词
benzamides; nicotinamides; apoptosis; inflammation; NF-kB; DNA repair;
D O I
暂无
中图分类号
学科分类号
摘要
Our laboratory has concentrated on the possible regulation the benzamides and nicotinamides may have on the processes of DNA repair and apoptosis. Recent reports [14-16] have suggested that both apoptosis and inflammation are regulated by the transcription factor NF-kB. We have initiated studies regarding the hypothesis that the benzamides and nicotinamides could inhibit the production of tumor necrosis factor alpha (TNFalpha) and the inflammatory response as well as induce apoptosis via inhibition of NF-kB. Our data have shown that nicotinamide and two N-substituted benzamides, metoclopramide (MCA) and 3-chloroprocainamide (3-CPA), gave dose dependent inhibition of lipopolysacharide induced TNFalpha in the mouse within the dose range of 10-500 mg/kg. Moreover, lung edema was prevented in the rat by 3 ï 50 mg/kg doses of 3-CPA or MCA, and 100-200 μM doses of MCA could also inhibit NF-kB in Hela cells. Taken together these data strongly support the notion that benzamides and nicotinamides have potent anti-inflammatory and antitumor properties, because their primary mechanism of action is regulated by inhibition at the gene transcription level of NF-kB, which in turn inhibits TNFalpha and induces apoptosis.
引用
收藏
页码:119 / 125
页数:6
相关论文
共 109 条
[1]  
Horsman MR(1995)Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours Acta Oncol 34 571-587
[2]  
Harrington RA(1983)Metoclopramide. An updated review of its pharmacological properties and clinical use Drugs 25 451-494
[3]  
Hamilton CW(1998)Multiple modes of action of the benzamides and nicotinamides as sensitizers of radio-and chernotherapies. Opportunities for drug design Cancer Prev Det 22 225-236
[4]  
Brogden RN(1989)5–HT3 receptor antagonists Drugs Future 14 875-889
[5]  
Linkewich JA(1995)Progress in identifying clinical relevance of inhibition, stimulation and measurement of poly ADP-ribosylation Biochimic 77 385-393
[6]  
Romankiewicz JA(1993)Specific binding and active transport of nicotinamide in human leukernic K562 cells Biochem Pharmacol 45 1191-1200
[7]  
Heel RC(1995) measurement of DNA damage, DNA repair and NAD pools as indicators of radiosensitization by metoclopramide Carcinogenesis 16 1029-1035
[8]  
Pero RW(1996)DNA damage and repair in tumour and nontumour tissues of mice induced by nicotinamide Brit J Cancer 74 368-373
[9]  
Olsson A(1997)Pharmacokinetics, toxicity, side effects, receptor affinities and Pharmacol Toxicol 80 231-239
[10]  
Amiri A(1997) radiosensitizing effects of the novel metoclopramide formulations, Sensamiode and Neu-Sensamide Acta Oncol 36 321-328